Cargando…

Impact of Tenofovir Disoproxil‐Induced Fanconi Syndrome on Bone Material Quality: A Case Report

Tenofovir is a nucleotide analog reverse‐transcriptase inhibitor (NtARTI) used for treatment of chronic hepatitis B and human immunodeficiency virus (HIV). Fanconi syndrome (FS) is a condition affecting the proximal tubules of the kidney, leading to increased passage and impaired reabsorption of var...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hadzimuratovic, Benjamin, Haschka, Judith, Hartmann, Markus A, Blouin, Stéphane, Fratzl‐Zelman, Nadja, Zwerina, Jochen, Kocijan, Roland
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216132/ https://www.ncbi.nlm.nih.gov/pubmed/34189389 http://dx.doi.org/10.1002/jbm4.10506

Ejemplares similares

Quantitative Backscattered Electron Imaging of Bone Using a Thermionic or a Field Emission Electron Source
por: Hartmann, Markus A., et al.
Publicado: (2021)

Increased Osteocyte Lacunae Density in the Hypermineralized Bone Matrix of Children with Osteogenesis Imperfecta Type I
por: Mähr, Matthias, et al.
Publicado: (2021)

Identifying adult hypophosphatasia in the rheumatology unit
por: Feurstein, Julia, et al.
Publicado: (2022)

Poor adherence to parenteral osteoporosis therapies during COVID-19 pandemic
por: Kocijan, Roland, et al.
Publicado: (2021)

Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects
por: Lee, Sangmi, et al.
Publicado: (2021)

Fanconi syndrome induced by the long-term use of tenofovir disoproxil fumarate: a case report and literature review
por: Li, Jiayi, et al.
Publicado: (2023)

Dispensing anti-osteoporotic drugs changed during the COVID-19 pandemic
por: Kocijan, Roland, et al.
Publicado: (2022)

Pelvic Fractures—An Underestimated Problem? Incidence and Mortality Risk after Pelvic Fracture in Austria, 2010–2018
por: Behanova, Martina, et al.
Publicado: (2022)

Abnormal Bone Tissue Organization and Osteocyte Lacunocanalicular Network in Early‐Onset Osteoporosis Due to SGMS2 Mutations
por: Mäkitie, Riikka E., et al.
Publicado: (2021)

Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients
por: Yim, Hyung Joon, et al.
Publicado: (2022)

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
por: Wassner, Chanie, et al.
Publicado: (2020)

Tenofovir Disoproxil Fumarate-Associated Fanconi Syndrome in an Human Immunodeficiency Virus (HIV)-Uninfected Man Receiving HIV Pre-Exposure Prophylaxis
por: Khan, Soheb, et al.
Publicado: (2017)

Fractal-Based Analysis of Bone Microstructure in Crohn’s Disease: A Pilot Study
por: Haschka, Judith, et al.
Publicado: (2020)

Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B
por: Cui, Guangying, et al.
Publicado: (2015)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Kawuma, Aida N., et al.
Publicado: (2023)

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
por: Funderburg, Nicholas T., et al.
Publicado: (2016)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
por: Michienzi, Sarah M, et al.
Publicado: (2021)

Bone outcomes in virally suppressed youth with HIV switching to tenofovir disoproxil fumarate
por: Braithwaite, Kate, et al.
Publicado: (2021)

Tenofovir-disoproxil-fumarate: Elevation in ALP: case report
Publicado: (2020)

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
por: Hill, Andrew, et al.
Publicado: (2018)

Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate
por: Huhn, Gregory D, et al.
Publicado: (2019)

Adherence Predictors in Pregnant Women Living with HIV on Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate
por: Eke, Ahizechukwu C
Publicado: (2022)

Fanconi Syndrome Accompanied by Renal Function Decline with Tenofovir Disoproxil Fumarate: A Prospective, Case-Control Study of Predictors and Resolution in HIV-Infected Patients
por: Gupta, Samir K., et al.
Publicado: (2014)

Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate‐Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy
por: Bukkems, Vera E., et al.
Publicado: (2020)

Efficacy and Safety of Tenofovir Disoproxil Orotate in Chronic Hepatitis B Patients Previously Treated with Tenofovir Disoproxil Fumarate: Multicenter, Open-Label, Prospective Study
por: Chang, Young, et al.
Publicado: (2021)

Tenofovir as a Cause of Acquired Fanconi's Syndrome
por: Simon, Monisha, et al.
Publicado: (2023)

Circulating miRNAs Respond to Denosumab Treatment After 2 Years in Postmenopausal Women With Osteoporosis—the MiDeTe study
por: Messner, Zora, et al.
Publicado: (2022)

96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients
por: Liu, Zhihong, et al.
Publicado: (2023)

Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health
por: McComsey, Grace A., et al.
Publicado: (2018)

Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B
por: Suzuki, Kazuharu, et al.
Publicado: (2022)

Pregnancy Outcomes in Pregnant Women with HIV on Tenofovir Disoproxil Fumarate (TDF) Compared to Tenofovir Alafenamide (TAF)
por: Thimm, Matthew A., et al.
Publicado: (2022)

3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China
por: Hou, Jinlin, et al.
Publicado: (2021)

Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation
por: Cheng, Chih-Hsien, et al.
Publicado: (2023)

Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
por: Lim, Young-Suk, et al.
Publicado: (2023)

Hypokalemic paralysis secondary to tenofovir induced fanconi syndrome
por: Ramteke, Vishal V., et al.
Publicado: (2015)

Can We Trust Safety of Tenofovir Disoproxil in Patients with Decompensated Cirrhosis?
por: Oh, Hyunwoo, et al.
Publicado: (2017)

Osteopenia in a young man associated with the use of tenofovir disoproxil fumarate
por: Li, Chunmei, et al.
Publicado: (2022)

Increase in bone turnover markers in HIV patients treated with tenofovir disoproxil fumarate combined with raltegravir or efavirenz()
por: Oster, Yonatan, et al.
Publicado: (2020)

Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients
por: Seo, Jun-Won, et al.
Publicado: (2020)

Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing
por: Johnson, Kelly A, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_satg0cca6avb1525iirqpt8l5e